

Online Resource 3 – Table 1. Characteristics of observation days, stratified by mental status on day X

Characteristic	All observation days (n = 24,906)	Mental status on day X ^a		
		Awake without delirium (n=12,169)	Delirium (n=4,708)	Unarousable (n=4,483)
mSOFA (IQR) ^a	5.0 (3.0-8.0)	5.0 (3.0-7.0)	6.0 (4.0-9.0)	9.0 (6.0-11.0)
Metabolic acidosis, n (%)	5,125 (20.6%)	1,932 (15.9%)	842 (17.9%)	2,019 (45.0%)
Use of mechanical ventilation, n (%)	18,220 (73.2%)	9,075 (74.6%)	3,964 (84.2%)	4,046 (90.3%)
Use of haloperidol, n (%)	3,216 (12.9%)	672 (5.5%)	2,211 (47.0%)	180 (4.0%)
Haloperidol dose in mg (IQR) ^b	2.4 (1.2-4.0)	1.8 (1.2-3.0)	3.0 (1.8-4.2)	2.4 (1.8-4.0)
Use of clonidine, n (%)	4,194 (16.8%)	1,679 (13.8%)	1,634 (34.7%)	666 (14.9%)
Clonidine dose in mcg (IQR) ^b	462.8 (150.0-900.6)	342.4 (107.7-678.0)	605.0 (246.7-1074.5)	529.9 (174.8-1037.3)
Use of any antipsychotic other than haloperidol, n (%)	1,088 (4.4%)	608 (5.0%)	395 (8.4%)	63 (1.4%)
Use of benzodiazepines or propofol, n (%)	11,115 (44.6%)	4,538 (37.3%)	2,125 (45.1%)	3,836 (85.6%)
Use of opioids, n (%)	13,874 (55.7%)	6,195 (50.9%)	2,769 (58.8%)	3,660 (81.6%)

IQR: Interquartile range; mcg: microgram; mg: milligram; mSOFA: modified Sequential Organ Failure

Assessment (without central nervous system component)

^a Missing data were present for some observation days: current mental status on day X 3546 (14.2%); mSOFA 981 (3.9%).

^b Median dose is calculated only for observation days upon which haloperidol/clonidine was administered.

Online Resource 3 – Table 2. Administration of haloperidol and clonidine, stratified by delirium motor subtype on day X.

Medication use	Mixed/hyperactive delirium day (n=2581)	Hypoactive delirium day (n=2110)	p value
Haloperidol, n (%)	1475 (57.1%)	735 (34.8%)	<.001
Clonidine, n (%)	1201 (46.5%)	431 (20.4%)	<.001